Adage Capital Partners
CRVS icon

Adage Capital Partners’s Corvus Pharmaceuticals CRVS Stock Holding History

Adage Capital Partners’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.2M Hold
750,000
– – 0.02% 692
2026
Q1 		$11M Buy
+750,000
New +$12M 0.02% 670
2021
Q4 		– Sell
-200,000
Closed -$968K – 1038
2021
Q3 		$968K Buy
+200,000
New +$592K ﹤0.01% 914

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Adage Capital Partners's CRVS Position: Q2 2026 in Review

Adage Capital Partners held its Corvus Pharmaceuticals (CRVS) position steady in Q2 2026 at 750,000 shares worth $11.2M. The position accounts for 0.02% of the portfolio, ranked #692.

Adage Capital Partners first reported a position in CRVS in Q3 2021 and has held it in 3 quarters since. 174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Adage Capital Partners held 750,000 shares of Corvus Pharmaceuticals worth $11.2M as of Q2 2026.
  • Adage Capital Partners left its Corvus Pharmaceuticals share count unchanged in Q2 2026.
  • Corvus Pharmaceuticals made up 0.02% of Adage Capital Partners's portfolio in Q2 2026, its #692 holding.
  • Adage Capital Partners first reported a position in Corvus Pharmaceuticals in Q3 2021 and has held it in 3 quarters since.
  • 174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.